Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts.

How much of Beam Therapeutics (BEAM) revenue comes from haram?

As of December 31, 2021, Beam Therapeutics has no revenue from product sales since they are still in the research and development phase. Currently, their only source of revenue is from license and collaboration agreements.

Practical Islamic Finance concludes:

None of Beam Therapeutics Inc.’s Revenue comes from anything inherently haram.

Does Beam Therapeutics (BEAM) rely on interest to operate?

 Fiscal Year ended 12/31/2021Fiscal Year ended 12/31/2020Fiscal Year ended 12/31/2019
Interest Expense567561187
Total Operating Expense444,309132,78475,172
Interest Expense / Total Operating Expense0.13%0.42%0.25%

*Numbers in thousands, of U.S. dollars

Practical Islamic Finance concludes:

Riba is used but not relied upon in Beam Therapeutics Inc.’s operations.

What are Beam Therapeutics (BEAM)’s Environmental, Social, and Governance (ESG) Impact?

Environment

No notable environmental highlights.

Social

Beam Therapeutics Inc. is developing a portfolio of product candidates in disease areas such as hematology, oncology, liver diseases, and CNS diseases. This novel gene technology, if successful will be of great benefit to humanity.

Beam Therapeutics Inc. has a Glassdoor rating of 4.7 out of 5.0. They are continually ranked in the top 10 places to work by Boston Globe’s survey for the last 3 years.

Governance

No notable governance highlights.

Practical Islamic Finance concludes: 

Beam Therapeutics Inc. has a net positive ESG impact. 

Comfort Rating 

From Beam Therapeutics (BEAM)’s business, financial, and ESG reviews, Practical Islamic Finance rates Beam Therapeutics (BEAM) stock as: 

Comfortable to invest in from a halal perspective.

Sources

10K Dec 2021

Glassdoor Rating

Beam Therapeutics Inc. Governance Policy

Author